Your browser doesn't support javascript.
loading
Development and characterisation of suitably bioengineered microfibrillar matrix-based 3D prostate cancer model forin vitrodrug testing.
Thilakan, Akhil T; Nandakumar, Niji; Balakrishnan, Arvind R; Pooleri, Ginil K; Nair, Shantikumar V; Sathy, Binulal N.
Affiliation
  • Thilakan AT; Amrita Centre for Nanosciences and Molecular Medicine, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
  • Nandakumar N; Amrita Centre for Nanosciences and Molecular Medicine, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
  • Balakrishnan AR; Amrita Centre for Nanosciences and Molecular Medicine, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
  • Pooleri GK; Department of Urology and Renal Transplantation, Amrita Institute of Medical Sciences and Research, Kochi, Kerala, India.
  • Nair SV; Amrita Centre for Nanosciences and Molecular Medicine, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
  • Sathy BN; Amrita Centre for Nanosciences and Molecular Medicine, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
Biomed Mater ; 18(6)2023 Oct 13.
Article in En | MEDLINE | ID: mdl-37738986
ABSTRACT
Bioengineered 3D models that can mimic patient-specific pathologiesin vitroare valuable tools for developing and validating anticancer therapeutics. In this study, microfibrillar matrices with unique structural and functional properties were fabricated as 3D spherical and disc-shaped scaffolds with highly interconnected pores and the potential of the newly developed scaffolds for developing prostate cancer model has been investigated. The newly developed scaffolds showed improved cell retention upon seeding with cancer cells compared to conventional electrospun scaffolds. They facilitated rapid growth and deposition of cancer-specific extracellular matrix through-the-thickness of the scaffold. Compared to the prostate cancer cells grown in 2D culture, the newly developed prostate cancer model showed increased resistance to the chemodrug Docetaxel regardless of the drug concentration or the treatment frequency. A significant reduction in the cell number was observed within one week after the drug treatment in the 2D culture for both PC3 and patient-derived cells. Interestingly, almost 20%-30% of the cancer cells in the newly developed 3D model survived the drug treatment, and the patient-derived cells were more resistant than the tested cell line PC3. The results from this study indicate the potential of the newly developed prostate cancer model forin vitrodrug testing.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Biomed Mater Journal subject: ENGENHARIA BIOMEDICA Year: 2023 Document type: Article Affiliation country: India

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Biomed Mater Journal subject: ENGENHARIA BIOMEDICA Year: 2023 Document type: Article Affiliation country: India